Clinical Trial Detail

NCT ID NCT03004183
Title SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jenny C. Chang, MD
Indications

triple-receptor negative breast cancer

lung non-small cell carcinoma

Therapies

Pembrolizumab

AdV-tk + Valacyclovir

Age Groups: adult senior

No variant requirements are available.